Archive for the ‘Crispr’ Category

The team at MBL, led by MBL Senior Scientist Joshua Rosenthal and Crawford, has achieved the first gene knockout in a cephalopod using the squid Doryteuthis pealeii, an exceptionally important research organism in biology for nearly a century.

The team used CRISPR-Cas9 genome editing to knock out a pigmentation gene in squid embryos, which eliminated pigmentation in the eye and in skin cells (chromatophores) with high efficiency.

This is a critical first step toward the ability to knock out and knock in genes in cephalopods to address a host of biological questions, Rosenthal says.

Cephalopods (squid, octopus and cuttlefish) have the largest brain of all invertebrates, a distributed nervous system capable of instantaneous camouflage and sophisticated behaviors, a unique body plan, and the ability to extensively recode their own genetic information within messenger RNA, along with other distinctive features. These open many avenues for study and have applications in a wide range of fields, from evolution and development, to medicine, robotics, materials science, and artificial intelligence.

The ability to knock out a gene to test its function is an important step in developing cephalopods as genetically tractable organisms for biological research, augmenting the handful of species that currently dominate genetic studies, such as fruit flies, zebrafish, and mice.

CRISPR-Cas9 worked really well in Doryteuthis; it was surprisingly efficient, Rosenthal says. Much more challenging was delivering the CRISPR-Cas system into the one-celled squid embryo, which is surrounded by an exceedingly tough outer layer, and then raising the embryo through hatching. The team developed micro-scissors to clip the eggs surface and a beveled quartz needle to deliver the CRISPR-Cas9 reagents through the clip.

Studies with Doryteuthis pealeii have led to foundational advances in neurobiology, beginning with description of the action potential (nerve impulse) in the 1950s, a discovery for which Alan Hodgkin and Andrew Huxley became Nobel Prize laureates in 1963. For decades D. pealeii has drawn neurobiologists from all over the world to the MBL, which collects the squid from local waters.

Recently, Rosenthal and colleagues discovered extensive recoding of mRNA in the nervous system of Doryteuthis and other cephalopods. This research is under development for potential biomedical applications, such as pain management therapy.

For these reasons, the MBL Cephalopod Programs next goal is to transfer the new knockout technology to a smaller cephalopod species, Euprymna berryi (the hummingbird bobtail squid), which is relatively easy to culture to make genetic strains.

The MBL Cephalopod Program is part of the MBLs New Research Organisms Initiative, which is widening the palette of genetically tractable organisms available for research and thus expanding the universe of biological questions that can be asked.

This entry was posted on July 31, 2020 at 4:14 am and is filed under All News, Community, County, Education, More News, St. Mary's News, z 600X120 Top Ad Bottom, z 600X120 Top Ad Top. You can follow any responses to this entry through the RSS 2.0 feed.

See original here:
First Gene Knockout in a Cephalopod is Achieved at Marine Biological Laboratory by Professor Karen Crawford and Team | Southern Maryland News Net -...

BOSTON, July 28, 2020 /PRNewswire/ -- Breakthrough Properties announced that leading gene editing company, CRISPR Therapeutics, has signed a 263,500-square-foot lease agreement for the development referred to as "The 105," located at 105 West First Street and scheduled for completion in early 2022. The full-building lease transaction was executed just one year after acquisition of the site in July 2019 and four months after groundbreaking.

Breakthrough Properties was launched in 2019 by Tishman Speyer, one of the world's leading real estate developers and owners, and Bellco Capital, a prominent biotechnology investment firm. Breakthrough was formed to acquire, develop and operate the finest life science properties in leading technology centers around the world, supporting scientific innovation across biotechnology, agriculture and nutrition. On The 105 project, the company has been working closely with Tishman Speyer's Boston-based team every step of the way, from site selection to future project completion.

The 105 has been designed by the Payette architecture firm to be a best-in-class laboratory building to accommodate tenants at the forefront of life-changing science. Conveniently located near the Red Line's Broadway Station, it will feature a tailored array of amenities, including a fitness facility and outdoor terraces accessible from two floors. LEED Gold and Fitwel certifications will be sought.

Breakthrough Properties Chief Executive Officer Dan Belldegrun commented, "Our mission at Breakthrough is to deliver cutting edge facilities and environments that support companies at the forefront of life-changing science.We are thrilled to partner with CRISPR, one of the world's emerging leaders in the biotech industry, as it continues to develop therapies that change the way we fight disease. There has never been a more important time to focus on the scientific innovation and we're honored to play a small but supportive role in CRISPR's exciting future."

Tishman Speyer President & Chief Executive Officer Rob Speyer said, "With Breakthrough Properties, we are combining Tishman Speyer's global property development capabilities with Bellco Capital's recognized life sciences expertise and strong relationships. It's already proving to be a great collaboration. We believe Breakthrough will become a major global player in creating the next generation of research facilities, where important scientific advances will take place to benefit people around the world."

Since its founding in 2013, CRISPRhas quickly grown to be a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases. CRISPR has established a portfolio of therapeutic programs across a broad range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Brokerage firm Cushman & Wakefield represented CRISPR, while Breakthrough was represented by Newmark Knight Frank.

About Breakthrough Properties (btprop.com)

Breakthrough Properties is a life science real estate development company that leverages cross-sector collaboration to deliver environments that foster innovation and scientific breakthroughs. Breakthrough combines Tishman Speyer's decades of global real estate development experience with Bellco Capital's industry-making biotechnology entrepreneurship to reimagine environments where companies can create life-changing therapies for patients. At Breakthrough, we seek to be a home for scientific discovery and innovation because we understand what you do, how you do it and why you do it.

Environments that foster innovation. Discoveries that transform lives.

For more information, please visit http://www.btprop.com.

SOURCE Breakthrough Properties

http://www.btprop.com

Go here to see the original:
Breakthrough Properties Executes Full-Building Lease With Leading Gene Editing Company for Next Generation Life Science Development in Boston's...

Dublin, July 31, 2020 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools, and Reagents: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Gene and cell therapy are emerging as important tools to treat human health. Techniques such as CAR-T therapy have emerged as key ways of treating many different types of cancers. The promise of gene therapy using technologies such as CRISPR is starting to be realized in clinical trials, and markets are scaling up to treat other diseases as well, particularly rare gene-based diseases. As these therapies are coming to the fore, a new market for tools to develop these therapies using standard methodologies is emerging. This report will cover what those tools are, how they impact the larger life science tools market, and how they will evolve over the next five years.

The scope of this study encompasses an investigation of the market's cell and gene therapy tools such as GMP proteins, media, cell separation and activation reagents, viral and non-viral, cytokine release syndrome monitoring products, GMP antibodies, leukapheresis instrumentation, immunoassays (multiplex and singleplex) and bioreactors. This research analyzes each tool type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed. The report analyzes the industry on a worldwide basis, from both application and demand perspectives, in the major regions of the world.

The Report Includes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Breakdown by Region

Chapter 5 Market Breakdown by End User

Chapter 6 Government Regulations

Chapter 7 Patent Review/New Developments

Chapter 8 Analysis of Market Opportunities

Chapter 9 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/86txdi

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

More:
Global Market Trends in the Cell and Gene Therapy Tools and Reagents Market 2020-2024 - GlobeNewswire

The Hackett Group at EMBL Rome explores epigenetics, genome regulation and cell identity. Recently, the scientists developed a novel CRISPR molecular tool for editing the epigenome, enabling transient modifications that can switch certain genes "on" and "off" temporarily.The SARS-CoV-2 virus that has caused the COVID-19 global pandemic makes its way into a host cell via a protein known as ACE2, which is involved in a range of physiological functions in the body.

What happens when you transiently turn "off" the gene that encodes this protein? Can SARS-Cov-2 still enter the cell and cause infection? This is what Hackett and colleagues are currently exploring in animal models, to determine whether epigenetic silencing could be a treatment approach for COVID-19 in humans.Technology Networks spoke with Dr James (Jamie) Hackett, group leader at EMBL, to learn more about the CRISPR tool, how it can be used to silence ACE2 in the context of SARS-CoV-2 infection and whether there could be any adverse implications from doing so.Molly Campbell (MC): For our readers that may be unfamiliar, can you please describe what epigenetic modifications are?Jamie Hackett (JH): Epigenetic modifications are small chemical tags that are physically grafted onto DNA (or the histones that DNA wraps around) to help control how and when the DNA is used. These epigenetic modifications act as signposts that encourage a specific part of DNA, such as a gene, to be switched on or off. In other words, they help control which genes are "expressed", and which are ignored in each cell. This is important to ensure that genes that are required specifically in liver, for example, are only switched on in the liver, and not say, in the brain.MC: You are developing a CRISPR-based molecular tool to conduct epigenetic editing. Can you please tell us about this approach? How have you developed the tool and how does it work?JH: CRISPR systems normally locate a specific section of DNA in the genome and alter its genetic sequence, known as genetic "editing". Epigenetic editing uses the same principle but instead alters the epigenetic modifications at a specific region rather than the genetic sequence. This turns genes on or off in a "programmable" manner. Importantly, unlike genetic editing, epigenetic editing is largely reversible, enabling transient changes in how genes operate without changing the DNA sequence itself.MC: You plan to test the tool in mice to target airway cells that express the ACE2 protein. Can you talk to us about the rationale behind this?JH: ACE2 is a protein that sits on the outside of many cells and is normally involved in controlling blood pressure. However, the COVID-19 virus hijacks ACE2 by using it as a docking site that enables entry of the virus into a cell. If the gene ACE2 is switched OFF, this should remove the access point for COVID-19 and restrict infection. To test this possibility, we will use mouse models where we attempt to epigenetically switch off ACE2, which will help inform us whether this could be a viable strategy in humans in the future.

MC: Could there be adverse effects from targeting the ACE2 protein, as it is involved in several physiological processes in humans, for example? How will you explore and monitor this?JH: Impaired levels of ACE2 over long periods are linked with elevated blood pressure. However, over short-term periods loss of ACE2 appears to be relatively tolerable. This is one reason why a reversible "epigenetic" approach could be appealing since it would only temporality deplete ACE2 from cells, potentially to provide protection during high risk periods, before allowing it to return to its original status at the appropriate time.MC: What broader applications might this tool have, beyond SARS-CoV-2?JH: The same technology can, in principle, be applied to change the expression of genes other than ACE2, that are linked with disease. We are at the very beginning of exploring the potential of this, so it is not clear what realistic expectations are, but there is nonetheless great excitement about such precision strategies. For example, diseases where one of the two gene copies is a "mutant", such as Huntingtons disease, could be targets. Here it is hoped to be possible to epigenetically switch off only the mutant version of the gene, leaving the normal copy on. This scenario is predicted to help mitigate symptoms in a very precise and specific way. Conversely, in the neurological disorder Fragile X syndrome, the FMR1 gene has become inappropriately silenced (switched off). Epigenetic editing can be applied to selectively reactivate this gene to switch it on, with initial indications being that this helps restore neuronal functions. Jamie Hackett was speaking to Molly Campbell, Science Writer for Technology Networks.

Go here to see the original:
Silencing the SARS-CoV-2 Receptor With CRISPR and Epigenetic Modifications - Technology Networks

There are good investments and there are great investments. CRISPR Therapeutics (NASDAQ:CRSP) stock certainly qualifies as the latter.

This is a company that, four years after it went public, has only been profitable for one year, yet its future is so promising that its stock is trading for 540% more than it did in 2016.

What's the big deal about CRISPR Therapeutics? The biopharmaceutical company says it is using breakthrough gene-altering therapies to treat diseases such as sickle cell disease (SCD) and beta-thalassemia, both of which are inherited blood disorders that don't have a cure and require frequent blood transfusions. The company is also working on gene therapies to treat type 1 diabetes, muscular dystrophy, cystic fibrosis, multiple myeloma, and solid tumors in pancreatic cancer and lung cancer.

Image source: Getty Images.

CRISPR Therapeutics is actually named for the technology it uses: CRISPR stands for "clusters of regularly interspaced short palindromic repeats." The gene-editing technology uses Cas9 proteins to locate a sequenceof DNA within a cell and alter it.

Though CRISPR Therapeutics has yet to bring a product to market, some of its clinical trials have had amazing results. In June, the Swiss company announced that in a joint trial with Vertex Pharmaceuticals (NASDAQ:VRTX), five patients with beta-thalassemia and two patients with sickle cell disease were treated with gene therapy CTX001.

Two of the early beta-thalassemia patients are now transfusion independent 15 months afterward. The first SCD patient in the trial is transfusion independent and free of vaso-occlusive crises (VOCs), a painful condition when blood vessels are blocked by sickled red blood cells, seven months after his dose of CTX001.

Beta-thalassemia, which reduces the body's production of hemoglobin, is extremely rare. Sickle cell anemia is common among African Americans but also can affect Latinos and people of Indian, Asian, Mediterranean backgrounds. The U.S. Department of Health and Human Services says 300,000 babies worldwide are born every year with the disease and 100,000 people in the United States are currently living with the disease.

While the results are quite promising, the study is still in its infancy. .

If you had invested $100 in CRISPR Therapeutics stock when it went public in 2016, how much would that be worth today?

By the end of the day on Oct. 19, 2016, the day CRISPR Therapeutics went public, the stock was trading at $14.09, you would have bought seven shares. Assuming you bought at that price, your original $98.63 investment would be worth $632.45 as of the close of trading Friday when the stock went for $90.35 per share. That's a gain of 541%.

CRISPR Therapeutics isn't the only biotech to use CRISPR-Cas9 technology. Others include Editas Medicine (NASDAQ:EDIT) and Intellia Therapeutics (NASDAQ:NTLA), both of which went public in 2016. Neither of those has done quite as well as CRISPR Therapeutics since its IPO.

Compared to a biotech ETF such as the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB), CRISPR has shined. The ETF closed at $89.16 on the day of CRISPR's IPO. As of Friday's close, IBB was at $136.41. If you had invested $100 on Oct. 19, 2016, you would have a return of only 36%.

CRSP data by YCharts

Clinical-stage biotech stocks are inherently risky plays because there are so many hurdles these companies have to clear before they can make money. The therapies have to be approved by the Food and Drug Administration (FDA) and many therapies look promising only to fail in late-stage clinical trials.

CRISPR Therapeutics looks like a solid bet, though, both from a cash standpoint and in its strength of pipeline. The company has four candidates already in trials.It is already making money, though not a lot of it. Last year, CRISPR Therapeutics generated net income of $66.8 million, thanks to $289.5 million in collaboration revenue.

The other major question for clinical-stage biotechs is whether they have enough capital to pay for research and development until the therapies pay off. Last quarter, the company burned through $54 million in cash. However, CRISPR Therapeutics says it has more than $900 million left, so it can continue that burn rate for more than four years. The possibility that CRISPR Therapeutics' technology could actually cure diseases, not just treat them, easily makes this a risk worth taking.

Original post:
If You Invested $100 in CRISPR Therapeutics' IPO, This Is How Much Money You'd Have Now - The Motley Fool

New Jersey, United States,- The research report on Crispr And Crispr Associated Genes market comprises of insights in terms of pivotal parameters such as production as well as the consumption patterns alongside revenue estimations for the projected timeframe. Speaking of production aspects, the study offers an in-depth analysis regarding the manufacturing processes along with the gross revenue amassed by the leading producers operating in this business arena. The unit cost deployed by these producers in various regions during the estimated timeframe is also mentioned in the report.

Significant information pertaining to the product volume and consumption value is enlisted in the document. Additionally, the report contains details regarding the consumption graphs, Individual sale prices, and import & export activities. Additional information concerning the production and consumption patterns are presented in the report.

In market segmentation by manufacturers, the report covers the following companies-

Exploring the growth rate over a period

Business owners looking to scale up their business can refer this report that contains data regarding the rise in sales within a given consumer base for the forecast period, 2020 to 2027. Product owners can use this information along with the driving factors such as demographics and revenue generated from other products discussed in the report to get a better analysis of their products and services. Besides, the research analysts have compared the market growth rate with product sales to enable business owners to determine the success or failure of a specific product or service.

By Type

By Application

Regions Covered in the Global Crispr And Crispr Associated Genes Market:

The Middle East and Africa (GCC Countries and Egypt)

North America (the United States, Mexico, and Canada)

South America (Brazil etc.)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Highlights of the Report:

Accurate market size and CAGR forecasts for the period 2020-2026

Identification and in-depth assessment of growth opportunities in key segments and regions

Detailed company profiling of top players of the global Crispr And Crispr Associated Genes market

Exhaustive research on innovation and other trends of the global Crispr And Crispr Associated Genes market

Reliable industry value chain and supply chain analysis

Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

The scope of the Report:

The report offers a complete company profiling of leading players competing in the global Crispr And Crispr Associated Genes marketwith a high focus on the share, gross margin, net profit, sales, product portfolio, new applications, recent developments, and several other factors. It also throws light on the vendor landscape to help players become aware of future competitive changes in the global Crispr And Crispr Associated Genes market.

Reasons to Buy the Report:

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

See the rest here:
Crispr And Crispr Associated Genes Market Growth Forecast Analysis Manufacturers, Regions, Type and Application to 2027 - Owned

CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2020. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus Estimate

This company is expected to post quarterly loss of $0.92 per share in its upcoming report, which represents a year-over-year change of +8.9%.

Revenues are expected to be $23.08 million, up 7112.5% from the year-ago quarter.

Estimate Revisions Trend

The consensus EPS estimate for the quarter has been revised 1.24% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings Whisper

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for CRISPR Therapeutics AG?

For CRISPR Therapeutics AG, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +13.78%.

Story continues

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that CRISPR Therapeutics AG will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?

Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that CRISPR Therapeutics AG would post a loss of $1.09 per share when it actually produced a loss of $1.15, delivering a surprise of -5.50%.

Over the last four quarters, the company has beaten consensus EPS estimates two times.

Bottom Line

An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

CRISPR Therapeutics AG doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCRISPR Therapeutics AG (CRSP) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Go here to see the original:
Will CRISPR Therapeutics AG (CRSP) Report Negative Q2 Earnings? What You Should Know - Yahoo Finance

The 105. Image courtesy of Payette

One year after forming a firm to acquire, develop and operate life sciences assets, Breakthrough Properties has signed a 263,500-square-foot lease agreement for its first ground-up development, The 105 in Bostons Seaport District. Located at 105 W. First St., the building will be fully leased by gene editing company CRISPR Therapeutics once it is completed in 2022.

READ ALSO: Life Sciences Real Estate Thrives Amid Pandemic

Breakthrough Properties was launched in 2019 by real estate development firm Tishman Speyer and Bellco Capital, a biotech investment company. The firm is targeting life science developments in leading tech markets around the globe for companies involved in the biotech, agriculture and nutrition sectors. Breakthrough acquired the Seaport property in July 2019 and broke ground on The 105 in March 2020. The firm has been working closely with Tishman Speyers Boston-based team throughout the process, including site selection, and will continue the close working relationship through the projects completion.

CRISPR, which currently has its R&D operations in Cambridge, Mass., plans to consolidate various office and laboratory operations in the Greater Boston area into the new Seaport building. The company was founded in 2013 and has grown into a leading gene-editing company focused on developing transformative gene-based medicines for a broad range of diseases. The parent company, CRISPR Therapeutics AG, is headquartered in Zurich and the wholly owned U.S. subsidiary CRISPR Therapeutics also has business offices in San Francisco and London. Officials said this week that the single Boston location should support its anticipated growth for five to seven years from occupancy in 2022. CRISPR also announced Monday in its second-quarter 2020 earnings report that it is building a new cell therapy and manufacturing facility in Framingham, Mass.

Breakthrough Properties CEO Dan Belldegrun said Breakthroughs mission is to deliver cutting-edge facilities and environments that support companies like CRISPR. He noted in prepared remarks that the company was honored to play a small but supportive role in CRISPRs future as it develops therapies that change the way we fight disease.

Located on the A Street Corridor, The 105 is located near the Red Lines Broadway Station and a 10-minute ride from Kendall Square in Cambridge. Designed by the Payette architecture firm to be a best-in-class laboratory asset, Breakthrough will be seeking LEED Gold and Fitwell certifications for the building. Amenities will include a fitness center, indoor bicycle room, outdoor terraces accessible from the second and third floors, meeting space, and a locker room with showers.

Cushman & Wakefield represented CRISPR and Breakthrough was represented by Newmark Knight Frank in the lease transaction.

Last month, Hines also entered the life sciences market, unveiling a new partnership with 2ML Real Estate to develop a biotech and mixed-use hub in Houston. Levit Green will span more than 52 acres and be adjacent to the Texas Medical Center, the worlds largest cluster of medical facilities and businesses. 2ML is supplying the land for the project. Preliminary plans call for a mix of research, office, residential, retail and dining uses, along with outdoor amenities and green space.

Hines and Tishman Speyer are among a growing group of commercial real estate developers expanding recently into the burgeoning life sciences sector. Boston Properties teamed up with Alexandria Real Estate Equities in January to develop a 1.7 million-square-foot life science campus in South San Francisco. In October, LaSalle Investment Management took a stake in the San Diego headquarters of Illumina, a DNA sequencing and array-based technologies firm. Last summer, Thor Equities launched its Thor Sciences division to invest in biotech properties.

See the article here:
Breakthrough Properties Completes Full-Building Lease in Boston - Commercial Property Executive

Scientists at the University of WisconsinMadison have published a proof-of-concept method to correct an inherited form of macular degeneration that causes blindness, and that is currently untreatable.

Andrew Hellpap608-225-5024ahellpap@uwhealth.org

The researchers were able to correct the disease in stem cells from patients with BEST1 mutations by overwhelming broken copies of the gene with many functional copies of BEST1. This approach worked for most, but not all, of the BEST1 mutations that they tested. As an alternative approach for mutations that did not respond to this gene augmentation method, the team used CRISPR-Cas9 gene editing to target and correct the mutations.

A paper chronicling the research, co-led by David Gamm, MD, PhD, professor of ophthalmology and visual sciences in the School of Medicine and Public Health, was published online July 23 in the American Journal of Human Genetics. The study was also led by Kris Saha, PhD, associate professor of biomedical engineering and Wisconsin Institute for Discovery, and Bikash Pattnaik, PhD, assistant professor of pediatrics.

This BEST1 gene encodes a protein that regulates the movement of chloride across a layer of the retina called the retinal pigment epithelium (RPE). Best disease is dominant, meaning that people who inherit only one faulty copy of the BEST1 gene from either their mother or their father will develop the disorder. Mutations in BEST1 cause the retinal layer to break down, resulting in blurred central vision that progresses to irreversible vision loss.

People with Best disease have a wide range of mutations that can affect different parts of the protein, all of which were thought to require complex, individualized gene therapies to fix them, Gamm said. We found that many of these mutations were actually very sensitive to a broader gene therapy method that is already established for other retinal diseases.

Fixing a dominant genetic disease via gene therapy typically requires precise removal or repair of the nonfunctional gene without causing harm to the functional gene a difficult task that is frequently unsuccessful. In contrast, recessive genetic diseases that arise when a person inherits two nonfunctional genes one from each parent can be corrected by a technique called gene augmentation. This well-established process introduces a functional copy of the gene to fill the void.

To use another analogy, dominant mutations produce workers that actively look to sabotage the efforts of their capable coworkers, whereas recessive mutations produce proteins that never show up for work at all, Gamm said. As it turns out, the latter situation is usually simpler to treat than the former.

A team of researchers at the McPherson Eye Research Institute, which Gamm directs, hypothesized that it may be possible to adequately dilute the influence of the nonfunctional BEST1 protein by counter-balancing it with many functional copies of BEST1 protein through gene augmentation.

In the lab, the approach worked in RPE cells derived from induced pluripotent stem cells of patients with most, but not all, of the BEST1 gene mutations they tested. Where gene augmentation did not succeed, the team was able to correct the dysfunction using CRISPR-Cas9 gene editing.

The research was carried out in large part by Divya Sinha, PhD, an assistant scientist in Gamms lab, Ben Steyer, a former MD-PhD student in Sahas lab, and Pawan Shahi, PhD, postdoctoral research associate in Pattnaiks lab. The research team also included Sushmita Roy, PhD, associate professor of biostatics and medical informatics at the UW School of Medicine and Public Health and Wisconsin Institute for Discovery.

The scientists demonstrated that their two-pronged gene therapy strategy may hold potential to treat all Best disease mutations in a highly effective manner.

We were able to reverse the disease in all the cell lines using one method or the other, Gamm said. We were also able to determine which mutations were likely to respond to the first-line gene augmentation strategy, and which would be better served with the second-line gene editing approach.

An additional benefit came into focus as this research progressed, according to Gamm.

Our findings also could be applicable to some dominant genetic mutations that affect tissues elsewhere in the body, he said. Its very exciting.

More here:
UW researchers devise approach to treat rare, incurable form of blindness - University of Wisconsin-Madison

DUBLIN--(BUSINESS WIRE)--The "Cell and Gene Therapy Tools, and Reagents: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Gene and cell therapy are emerging as important tools to treat human health. Techniques such as CAR-T therapy have emerged as key ways of treating many different types of cancers. The promise of gene therapy using technologies such as CRISPR is starting to be realized in clinical trials, and markets are scaling up to treat other diseases as well, particularly rare gene-based diseases. As these therapies are coming to the fore, a new market for tools to develop these therapies using standard methodologies is emerging. This report will cover what those tools are, how they impact the larger life science tools market, and how they will evolve over the next five years.

The scope of this study encompasses an investigation of the market's cell and gene therapy tools such as GMP proteins, media, cell separation and activation reagents, viral and non-viral, cytokine release syndrome monitoring products, GMP antibodies, leukapheresis instrumentation, immunoassays (multiplex and singleplex) and bioreactors. This research analyzes each tool type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed. The report analyzes the industry on a worldwide basis, from both application and demand perspectives, in the major regions of the world.

The Report Includes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Breakdown by Region

Chapter 5 Market Breakdown by End User

Chapter 6 Government Regulations

Chapter 7 Patent Review/New Developments

Chapter 8 Analysis of Market Opportunities

Chapter 9 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/nk3d0z

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

See more here:
Global Cell and Gene Therapy Tools and Reagents Market 2020: Analysis of Market Opportunities - ResearchAndMarkets.com - Business Wire

Genetic Technologies in Agriculture 2020-2030: Forecasts, Markets, Technologies

Genome editing (CRISPR, TALENs, ZFNs), Transgenics (GMOs), Synthetic Biology, and Breeding in Crop Agriculture: Technology and Market Analysis

By Dr Michael Dent

21st century agriculture is facing some major challenges. The global population is set to increase to over 10 billion by 2050, something the UN estimates will require a 70% from today's global food production. At the same, resources are dwindling - the loss of agricultural land stemming from climate change and urbanisation coupled with plateauing crop yields will present major challenges to every nation on Earth.

Genetic technologies in agriculture 2020-2030, a new report from IDTechEx, explores the use of biotechnology as a potential solution to these challenges. The report provides in-depth technical and market insight into the different genetic technologies used in crop agriculture, including transgenics (GMOs), genome editing techniques (CRISPR, TALENs, ZFNs, etc.) and breeding strategies, while also exploring the regulatory and industrial landscapes in which they operate. The report forecasts the future of the industry over the next decade, identifying genome editing technologies as a key growth area.

This is not the first time that world has faced a food crisis This is not the first time that the world has faced a food crisis due to plateauing yields and growing populations. In the 1960s, famine threatened much of Asia, with Paul Ehrlich's 1968 bestseller "The Population Bomb" predicting that famines centred in India would kill hundreds of millions across the following decades.

This bleak future was mostly avoided, largely thanks to the Green Revolution. Using selective breeding, American biologist Norman Borlaug created a high yield strain of wheat that led to more grain per acre, significantly boosting Mexico's agricultural output. Soon, similar strategies were used in India to develop high yield IR8 rice. These selective breeding strategies, alongside advances in fertiliser and mechanisation technologies led to a boom in global food production, with cereal production in Asia doubling between 1970 and 1995.

Selective breeding is just one of many techniques for manipulating the DNA of plants in agriculture to create improved seeds and traits. Over the past few decades, the genetic engineering tools available to scientists has expanded to include methods such as mutagenesis and transgenic breeding, the technique used to develop "genetically modified organisms" (GMOs). However, in recent years, technological advances such as next generation DNA sequencing and gene editing techniques such as TALENs, ZFNs and CRISPR-Cas9 have vastly expanded the capabilities of genetic engineering. This has led to much excitement in the field of agricultural biotechnology, with proponents hoping that modern genetic technologies could help usher in a new Green Revolution of agricultural productivity. Synthetic biology and manipulation of the crop microbiome could open a huge window of opportunities for boosting yields in previously inaccessible ways.

The report assesses the following:

Read more from the original source:
Feeding the World with Genetic Technologies: Technologies and Policies - IDTechEx.com

Plant Breeding and CRISPR Plant Industry 2020 Global Market Research report presents an in-depth analysis of the Plant Breeding and CRISPR Plant market size, growth, share, segments, manufacturers, and technologies, key trends, market drivers, challenges, standardization, deployment models, opportunities, future roadmap and 2025 forecast. The report additionally presents forecasts for Plant Breeding and CRISPR Plant market revenue, consumption, production, and growth drivers of the market.

The report forecast global Plant Breeding and CRISPR Plant market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2020-2025.The report offers detailed coverage of Plant Breeding and CRISPR Plant industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Plant Breeding and CRISPR Plant by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

You Can Get a Sample Copy of this Report at https://www.orianresearch.com/request-sample/1525974

Major Players in Plant Breeding and CRISPR Plant market are:

Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):

The scope of the Global Plant Breeding and CRISPR Plant Report:

Order a copy of Global Plant Breeding and CRISPR Plant Market Report @https://www.orianresearch.com/checkout/1525974

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.): Molecular Breeding Hybrid Breeding Genome Editing Genetic Engineering Conventional Breedi

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.): Oilseeds & Pulses Cereals & Grains Fruits & Vegetables Othe

Important Aspects of Plant Breeding and CRISPR Plant Report:

Why To Select This Report:

Complete analysis on market dynamics, market status and competitive Plant Breeding and CRISPR Plant view is offered.

Forecast Global Plant Breeding and CRISPR Plant Industry trends will present the market drivers, constraints and growth opportunities.

The five-year forecast view shows how the market is expected to grow in coming years.

All vital Global Plant Breeding and CRISPR Plant Industry verticals are presented in this study like Product Type, Applications and Geographical Regions.

Table of Contents

Part 1 Market Overview

Part 2 Global Market Status and Future Forecast

Part 3 Asia-Pacific Market Status and Future Forecast

Part 4 Asia-Pacific Market by Geography

Part 5 Europe Market Status and Future Forecast

Part 6 Europe Market by Geography

Part 7 North America Market Status and Future Forecast

Part 8 North America Market by Geography

Part 9 South America Market Status and Future Forecast

Part 10 South America Market by Geography

Part 11 Middle East & Africa Market Status and Future Forecast

Part 12 Middle East & Africa Market by Geography

Part 13 Key Companies

Part 14 Conclusion

Customization Service of the Report:-

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities

About Us:Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US +1 (415) 830-3727| UK +44 020 8144-71-27

Email: [emailprotected]

Read the original:
Plant Breeding and CRISPR Plant Market 2020 Segmentation, Application, Technology and Analysis Report Forecast to 2025 - Owned

Global CRISPR Technology Market: Trends Estimates High Demand by 2027

The CRISPR Technology Market 2020 report includes the market strategy, market orientation, expert opinion and knowledgeable information. The CRISPR Technology Industry Report is an in-depth study analyzing the current state of the CRISPR Technology Market. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on CRISPR Technology Market provides analysis of market covering the industry trends, recent developments in the market and competitive landscape.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global CRISPR Technology market. All findings and data on the global CRISPR Technology market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global CRISPR Technology market available in different regions and countries.

The final report will add the analysis of the Impact of Covid-19 in this report CRISPR Technology industry.

Some of The Companies Competing in The CRISPR Technology Market are: Thermo Fisher Scientific,Merck KGaA,GenScript,Integrated DNA Technologies (IDT),Horizon Discovery Group,Agilent Technologies,Cellecta, Inc.,GeneCopoeia, Inc.,New England Biolabs,Origene Technologies, Inc.,Synthego Corporation,Toolgen, Inc.

Get a Sample Copy of the [emailprotected] https://www.reportsandmarkets.com/sample-request/global-crispr-technology-market-professional-survey-2019-by-manufacturers-regions-types-and-applications-forecast-to-2024?utm_source=3wnews&utm_medium=46

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porters five techniques for analyzing the CRISPR Technology Market; it also offers the examination of the global market. To make the report more potent and easy to understand, it consists of info graphics and diagrams. Furthermore, it has different policies and improvement plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

Global CRISPR Technology Market Research Report 2020 carries in-depth case studies on the various countries which are involved in the CRISPR Technology market. The report is segmented according to usage wherever applicable and the report offers all this information for all major countries and associations. It offers an analysis of the technical barriers, other issues, and cost-effectiveness affecting the market. Important contents analyzed and discussed in the report include market size, operation situation, and current & future development trends of the market, market segments, business development, and consumption tendencies. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds.

What questions does the CRISPR Technology market report answer pertaining to the regional reach of the industry?

The report claims to split the regional scope of the CRISPR Technology market into North America, Europe, Asia-Pacific, South America & Middle East and Africa. Which among these regions has been touted to amass the largest market share over the anticipated duration

How do the sales figures look at present how does the sales scenario look for the future?

Considering the present scenario, how much revenue will each region attain by the end of the forecast period?

How much is the market share that each of these regions has accumulated presently

How much is the growth rate that each topography will depict over the predicted timeline

A short overview of the CRISPR Technology market scope:

Global market remuneration

Overall projected growth rate

Industry trends

Competitive scope

Product range

Application landscape

Supplier analysis

Marketing channel trends Now and later

Sales channel evaluation

Market Competition Trend

Market Concentration Rate

Reasons to Read this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

Chapter 1:CRISPR Technology Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:CRISPR Technology Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: CRISPR Technology Market Effect Factors Analysis

Chapter 12: GlobalCRISPR Technology Market Forecast to 2027

Get Complete Report @ https://www.reportsandmarkets.com/sample-request/global-crispr-technology-market-professional-survey-2019-by-manufacturers-regions-types-and-applications-forecast-to-2024?utm_source=3wnews&utm_medium=46

About Us:

Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Go here to read the rest:
Research On Global CRISPR Technology Market (impact of COVID-19) with Top Players: Thermo Fisher Scientific,Merck KGaA,GenScript and Others - 3rd...

The report titled CRISPR Technology Market has recently added by MarketResearch.Biz to get a stronger and effective business outlook. It provides a comprehensive analysis of different attributes of industries such as current and future trends, policies, and key players operating in several regions. The quantitative and qualitative analysis techniques have been used by analysts to provide accurate and applicable data to the readers, business owners and industry experts

The major players in global CRISPR Technology market include:

Thermo Fisher Scientific Inc, Merck KGaA, GenScript Corporation, Integrated DNA Technologies Inc, Horizon Discovery Group, Agilent Technologies Inc, Cellecta Inc, GeneCopoeia Inc, New England Biolabs Inc, Origene Technologies Inc

For Better Understanding, Download FREE Sample PDFCOPY of CRISPR Technology Market Research Report :https://marketresearch.biz/report/crispr-technology-market/request-sample

Quick Snapshot ofCRISPR TechnologyMarket Research Report Offerings:

COVID-19 Impact Analysis

Total Addressable Market [Present Market Size forecasted to 2029 with CAGR ]

Regional level split [North America, Europe, Asia Pacific, South America, Middle East & Africa]

Country-wise Market Size Split [countries with major market share]

Market Size Breakdown by Service/Product Types

Market Size by Industry verticals/End Users/Application/

Market Share and Revenue of 10-15 Top Companies in the Market

Production Capacity of Top Companies whenever applicable

Market Trends Emerging start-ups/ Technologies, PESTEL Analysis, Porters Five Forces, SWOT Analysis, etc.

Pricing Trend Analysis across regions

Brandwise Ranking of top Market Players globally

Download FREE Sample PDF Report Here

CRISPR Technology Market Segmented by product, application, and region

Segmentation on the basis of product:

LibraryPlasmids and VectorsProteinsOthers (Control Kits and gRNA)Segmentation on the basis of application:

Biological ResearchAgricultural BiotechIndustrial BiotechTherapeutics and Drug Discovery

The scope of the Global CRISPR Technology Report:

Regional scope North America (U.S., Mexico, Canada,), Europe (U.K., Germany; France; Italy; Russia; Spain, etc), South America (Brazil; Argentina, etc), Middle East & Africa (Saudi Arabia; South Africa, etc)

Methodology a combination of primary and secondary research

Report coverage market size, share, trends, statistics, challenges, opportunities, drivers, and restraints

Forecast period 2020-2029

Why Select This Report:

Complete analysis of market dynamics, market status, and competitive CRISPR Technology view is offered.

Forecast Global CRISPR Technology Industry trends will present the market drivers, constraints, and growth opportunities.

The ten-year forecast view shows how the market is expected to grow in the coming years.

All vital Global CRISPR Technology Industry verticals are presented in this study like Product Type, Applications, and Geographical Regions.

Inquire/Speak To Expert for Further Detailed Information About CRISPR Technology Market Research Report:https://marketresearch.biz/report/crispr-technology-market/#inquiry

Contact Us

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:inquiry:marketresearch.biz

Read this article:
CRISPR Technology Market 2020 : Recent Research Report Find Out Essential Strategies To Increase The Business - News Monitoring

[98 pages report] This market research report includes a detailed segmentation of the global genome editing market by technology (CRISPR, TALEN, ZFN, and Others), by application (Cell Line Engineering, Genetic Engineering, and Others), By end-user (Research Institutes, Biotechnology and Pharmaceutical Companies, and Contract Research Organizations), by regions (North America, Europe, Asia Pacific, and Rest of the World).

Request For Report[emailprotected]https://www.trendsmarketresearch.com/report/sample/9845

Overview of the Global Genome Editing Market

Infoholics market research report predicts that the Global Genome Editing Market will grow at a CAGR of 14.4% during the forecast period. The market has witnessed steady growth in the past few years with the development in technology and the introduction of highly sensitive, robust, and reliable systems in the market. The market is fueled due to increase in genetic disorders, increasing investment and funds, and technological advancements in genome editing.

The market continues to grow and is one of the increasingly accepted market in many countries worldwide. Vendors are focusing towards obtaining funds and collaborating with universities to enlarge their research and development capabilities. The majority of the revenue is generated from the leading players in the market with dominating sales of ThermoFisher Scientific, GenScript Corp., Sangamo Therapeutics, Lonza Group, and Horizon Discovery Group plc.

According to Infoholic Research analysis, North America accounted for the largest share of the global genome editing market in 2018. US dominates the market with majority of genome editing companies being located in this region. However, China has not been too far behind and has great government support for the research in genome editing field.

Genome Editing Market by Technology:

In 2018, the CRISPR segment occupied the largest share due to specific, effective, and cost-effective nature of the technology. Many companies are focusing on providing genome editing services. For instance, in January 2019, Horizon Discovery extended CRISPR screening service to primary human T cells.

Get Complete TOC with Tables and[emailprotected]https://www.trendsmarketresearch.com/report/discount/9845

Genome Editing Market by Applications:

In 2018, the cell line engineering accounted the maximum share followed by genetic engineering. Increase in the number of people suffering with genetic disorders has driven the growth of the genome editing market.

Genome Editing Market by End Users:

In 2018, the biotechnology and pharmaceutical companies gained the highest market share for genome editing market due to increased pervasiveness of cancer and infectious diseases are driving research goings-on in biotechnology & pharmaceutical companies segment.

Genome Editing Market by Regions:

The market is dominated by North America, followed by Asia Pacific and Europe. The major share of the North America market is from the US due to quick adoption of new and advanced technologies.

Genome Editing Market Research Competitive Analysis The market is extremely fragmented with several smaller companies struggling for market share. Big pharmaceutical establishments have also united with venture capitalists to provide funding to the start-ups. In 2015, Bayer financed $335 million and in the very same year, Celgene combined with Abingworth invested $64 million in CRISPR Therapeutics. The NIH recently granted 21 somatic cell genome editing grants of almost $86 million over the next half a decade. These endowments are the foremost to be granted through the Somatic Cell Genome Editing (SCGE) program that was initiated in January 2018 with NIH Common Fund.

The companies are collaborating and licensing to increase their capabilities in the market. CRISPR, TALEN, ZFN, Meganuclease, ARCUS, and RTDS are some of the key technology areas concentrated by key players in the market. Since 2015, the deals on the CRISPR technology has drastically increased.

Key vendors:

Key competitive facts

Benefits The report provides complete details about the usage and adoption rate of genome editing market. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical players initiatives, and government initiatives towards the healthcare segment in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.

<<< Get COVID-19 Report Analysis >>>https://www.trendsmarketresearch.com/report/covid-19-analysis/9845

Key Takeaways:

Original post:
Genome Editing Market to Exhibit Rapid Surge in Consumption in the COVID-19 Crisis 2025 - 3rd Watch News

The first company to win a Food and Drug Administration authorization for a CRISPR-based product is now, less than two months later, looking to develop an on-site diagnostic for Covid-19.

Cambridge, Massachusetts-based Sherlock Biosciences said Wednesday that it would partner with binx health, based in Boston, to develop a point-of-care test for Covid-19 using CRISPR technology. Sherlock received an emergency use authorization for its CRISPR-based Covid-19 test kit on May 7, becoming the first company ever to get a regulatory nod for a product using the gene-editing platform.

The companies will use Sherlocks CRISPR technology and binxs molecular testing system, called io, to develop a way to test for Covid-19 in retail and similar settings.

This collaboration with binx health to advance our Sherlock diagnostic platform and offer an accurate, point-of-care test is the next critical step in combating the global Covid-19 crisis, Sherlock CEO Rahul Dhanda said in a statement. We are also excited to explore with binx how to utilize the io platform to bring accurate and affordable testing to hospitals, urgent care centers and other healthcare facilities for a range of diagnostic tests beyond Covid-19.

Testing for Covid-19 whether RT-PCR or serological relies on samples being sent to central laboratories from the point of care, meaning it can take several days before patients learn whether or not they have the disease days in which they could still spread the virus if they do not self-isolate. That has led to an interest in point-of-care testing. However, the Food and Drug Administration has come under fire for granting an emergency use authorization for one rapid test, Abbotts ID NOW, amid reports that it is delivering inaccurate results.

Sherlock was co-founded by Broad Institute scientist Feng Zhang, one of the pioneers of CRISPR technology. Another company, South San Francisco, California-based Mammoth Biosciences whose technology is based on the research of fellow CRISPR pioneer Jennifer Doudna of the University of California Berkeley is partnered with GlaxoSmithKline to develop a CRISPR-based Covid-19 diagnostic.

Photo: jxfzsy, Getty Images

Read more:
Sherlock, binx to develop point-of-care Covid-19 test using CRISPR technology - MedCity News

The Herald

John CumbersSherlock Biosciences is partnering with binx health to not only bring to market the first point-of-care CRISPR product but also take the first step toward a new paradigm in health and diagnostics.

On January 4, 2018, Boston was shut down by a blizzard, but Rahul Dhanda was on a mission. A few months prior, the veteran of the diagnostics industry had gotten a call from David WaltHarvard professor and scientific founder of biotech heavyweight Illuminaabout a potential startup company Walt was exploring with synthetic biology pioneers Feng Zhang and Jim Collins. Despite the weather, Dhanda, in his business jacket and snow pants, trudged through two feet of snow to pitch his vision for that company to its founders. The day ended with dinner and one takeaway: Lets do it.

That company is Sherlock Biosciences, and just two years after that fateful January day, it received the first FDA Emergency Use Authorization for its CRISPR-based Covid-19 test, and was named a Technology Pioneer by the World Economic Forum.

Today, Sherlock announced that it has partnered with binx health to scale the rapid diagnostic test for point-of-care settings ranging from doctors offices to grocery stores. It represents not only the first point-of-care CRISPR product to come to market, but the first step toward a new paradigm in health and diagnostics.

Sherlocks namesake diagnostics platform, Specific High-sensitivity Enzymatic Reporter unLOCKing, is a technique that uses CRISPR to identify highly specific genetic sequences. Its the perfect tool for diagnosing Covid-19 by the presence of the novel coronavirus, which is discernible by its specific RNA sequence. The CRISPR system is adapted from the bacterial immune system and is best known for its ability to edit genes. Typically, CRISPR uses a piece of guide RNA as a WANTED poster to seek out a target gene of interest, which is then snipped by its enzymatic partner, the Cas9 molecular scissors.

The incredible precision of CRISPR has revolutionized gene editing. That same specificity also makes it a powerful tool for diagnostics, which is vital in fighting pandemics. While SHERLOCK does not utilize Cas9, it employs the same underlying principle of enzymatic molecular scissors. Guide RNA strands serve as scouts for a specific sequence of genetic material. When the guide meets the virus, the enzymatic scissors are activated and chop up a reporter-probe-quencher sequence, generating a fluorescent signal that shows the presence of the virus.

When run in the lab, Sherlocks diagnostic process produces results in under an hour. The companys new partnership with binx will scale the technology and bring the testing time down to as little as 20 minutes.

binxs FDA-approved and point-of-care testing system, binx io, is an easy-to-use desktop-sized instrument that has already made waves in testing for sexually transmitted infections. With its single-use cartridge system and the SHERLOCK platform installed, a binx io unit can analyze nasal swab samples and report a detected or not detected result for the novel coronavirus in under 30 minutes.

The speed and performance of binx io makes it incredibly competitive and best-in-class, says Dhanda. The decrease in time and increase in performance of SHERLOCK in conjunction with binxs platform creates an incredibly powerful way to manage the pandemic. By providing diagnostic screening in everyday locations, binx and Sherlock are meeting a need for Covid-19 testing that remains highly urgent months into this pandemic, especially as case counts continue to rise in the United States.

Pivoting to conquer a pandemicThe team at Sherlock recognized early this year that the health crisis unfolding in China would soon become a global threat. Within a matter of days, the Board of Directors made a unanimous and resounding decision to alter course to combat Covid-19. Sherlocks scientists responded with an inspiring demonstration of commitment, adaptability, and creativity. This quick turnaround to mitigate such a pressing problem speaks to the vast potential of Sherlock as a company.

Never in my career have I worked at a company able to pivot so quickly in the way we have with this technology to work on Covid-19, remarked Dhanda. Everyone here is smart enough to do something else, but theyre here because they want to be scientists making an impact and they believe in making a difference in healthcare. I was impressed with how we went from vision to implementation almost overnight, and how quickly that happened really speaks to the culture of the company.

In commercializing the worlds first FDA-authorized CRISPR product, we are learning about the value of rapid, rigorous execution for realizing the translational potential of engineering biology, adds Dr. Jim Collins. Our team at Sherlock Biosciences was remarkable in their demonstrated ability to go beyond ideas, concepts and academic papers, to a developed, authorized Covid-19 diagnostic test that is supported by extensive data and strong corporate partnerships.

The logistics side of the equationsupply chain, distribution, partners, regulatory compliance, and morealso seemed to fall into place in response to the Sherlock teams sheer drive and resilience. These were potential hurdles that Dhanda, in a pre-pandemic world, had given himself two years to overcome, but the swift repurposing of research also catalyzed delivery to market. The result has been a profound ripple effect throughout the diagnostics space.

Reimagining diagnostics, screening populationsTo date, Americas approach to Covid-19 testing has followed general trends in diagnostics. The scarcity of Covid-19 tests has forced healthcare providers to triage potential patients, prioritizing symptomatic individuals to confirm likely positive cases. While valuable and necessary, it is rare for these diagnostic results to make a difference in clinical care for patients, nor does such limited testing help researchers understand this deceptively complicated disease in a variety of populations.

The high-throughput testing facilitated by SHERLOCK and binx is an incredible way to deliver results that were inconceivable even five years agowere breaking the mold, says Dhanda. We tend to make decisions based on limited access to resources, and diagnostics have always been rationed. Covid-19 has just put a magnifying glass on that. But the unique restrictions placed on this industry start to fall away when we have new ways of getting results.

For Dhanda and Sherlock, the answerfor Covid-19 and beyondis moving away from reactive triage testing and towards broad-based screening, which allows researchers to better understand how a disease behaves in people and spreads throughout a population. Sherlock is uniquely poised to continue facilitating this shift to broad-based screening. In addition to the CRISPR-based SHERLOCK, the companys other technological cornerstone is the cell-free synthetic biology platform INSPECTR (Internal Splint-Pairing Expression Cassette Translation Reaction). INSPECTR shows great promise in the at-home testing market, thanks to its low cost, room temperature, and modular implementation..

[INSPECTR and SHERLOCK] are highly programmablewe can direct these tools towards anything wed like, explains Dhanda.

An at-home Covid-19 test through INSPECTR, while not yet a reality, is just one of many possibilities for the platform. INSPECTRs single-base specificity and rapid results could allow for crucial differentiation between influenza variants, drastically reduce the spread of infectious disease, add value to oncology, and even revolutionize non-medical industries such as agriculture and industrial testing. Much remains to be seen, but one thing is for certainwith the diagnostics market on the cusp of a transformation, Sherlock Biosciences is the company to watch.- Forbes

Original post:
A New 20-Minute Covid-19 Test Will Use CRISPR Gene Editing Technology To Deliver Results At The ... - The Herald

ZUG, Switzerland and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 6,428,572 common shares at a public offering price of $70.00 per share. In addition, the underwriters have a 30-day option to purchase up to an additional 964,285 common shares at the public offering price less the underwriting discount. CRISPR Therapeutics anticipates its gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $450.0 million, excluding any exercise of the underwriters option to purchase additional shares. The offering is expected to close on or about July 6, 2020, subject to customary closing conditions.

Goldman Sachs & Co. LLC, BofA Securities and Jefferies are acting as joint book-running managers for the offering. Canaccord Genuity, William Blair, SunTrust Robinson Humphrey and Roth Capital Partners are acting as co-managers for the offering.

The common shares will be offered and sold pursuant to the Companys previously filed automatically effective shelf registration statement on Form S-3 (File No. 333-227427) filed with the U.S. Securities and Exchange Commission (the SEC) on September 19, 2018. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on June 29, 2020. The final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SECs website at http://www.sec.gov. A copy of the final prospectus supplement may be obtained, when available, from Goldman Sachs & Co. LLC by mail at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; from BofA Securities by mail at NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; or from Jefferies, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340, or by email at prospectus_department@jefferies.com.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding CRISPR Therapeutics anticipated public offering. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, such as the expected closing date, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and the satisfaction of customary closing conditions related to the offering. These and other risks and uncertainties are described in greater detail in the section entitled Risk Factors in CRISPR Therapeutics Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on February 12, 2020, the prospectus supplement related to the public offering and other filings that CRISPR Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent CRISPR Therapeutics views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. CRISPR Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Story continues

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel EidesWCG on behalf of CRISPR+1 617-337-4167reides@wcgworld.com

Read more:
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares - Yahoo Finance

The Global CRISPR Technology Market 2020 Research Report is a professional and detailed study about the current and forecast state With COVID 19 Impact Analysis of the market.

MarketResearch.Biz offers a 360-degree view of the global CRISPR Technology market and offers accurate forecasting and also covers competitive landscapes, with in-depth market segmentation including type segment, industry segment, channel segment etc., vital trends and strategic recommendations to enable our clients. It also includes different clients data, which is very crucial for the manufacturers.

The historical information of the global CRISPR Technology market and evaluate the present market scenario based on the key factors determining the trajectory of this CRISPR Technology market with the help of primary and secondary data, the CRISPR Technology market research report projects the future and makes valid prediction. Moreover, the CRISPR Technology industry research report also incorporates insightful information from industry specialists to uplift readers to make well-informed business desicion. The CRISPR Technology market report also uses SWOT analysis and Porters five forces analysis to shed light on the important elements of the CRISPR Technology Market.

CLICK HERE !! To Know What Is The Impact Of COVID 19 On CurrentCRISPR Technology Market And How Market Will Grow In The Upcoming Period 2020-2029?

(***Our market experts are working day and night to identify, collect and timely deliver analysis on impact of unparalleled decisions of corporate executives in COVID-19 calamity on many businesses, their clients and their clients clients. We obeisance everyone who is doing their work in this economic and healthcare pandemic. Cordially Get in Touch for More Details Information.)

The report includes an reckoned impact of strict standards and regulations set by the government over the CRISPR Technology market in the forecast years. The market report also includes thorough research done using several analytical techniques such as SWOT analysis to identify the market growth pattern.

-We Do Offer FREE Sample Copy of this report. Kindly go through the following information in order to access the report.

** Note This report sample includes:

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by MarketResearch.Biz

For Better Understanding Go With This Free Sample Report Enabled With Respective Tables and Figures:https://marketresearch.biz/report/crispr-technology-market/request-sample

Major Players Are:

Thermo Fisher Scientific Inc, Cellecta Inc, GeneCopoeia Inc, GenScript Corporation, Merck KGaA, New England Biolabs Inc, Horizon Discovery Group, Origene Technologies Inc, Agilent Technologies Inc and Integrated DNA Technologies Inc

Market Segmentation:

Segmentation on the basis of product: Library, Plasmids and Vectors, Proteins, Others (Control Kits and gRNA). Segmentation on the basis of application: Biological Research, Agricultural Biotech, Industrial Biotech, Therapeutics and Drug Discovery

Regions & Countries Mentioned In The CRISPR Technology Market Report:

North America ( United States)

Europe ( Germany, France, UK)

Asia-Pacific ( China, Japan, India)

Latin America ( Brazil)

The Middle East & Africa

Some of the questions related to the CRISPR Technology market addressed in the report are:

With the developing demand, how are market players aligning their activities to fulfill the demand?

Which place has the most favorable regulatory rules to conduct commercial enterprise in the present CRISPR Technology market?

How has technological advances inspired the CRISPR Technology market?

At present, which organization has the very best market share in the CRISPR Technology market?

What is the maximum lucrative income and distribution channel used by market players in the worldwide CRISPR Technology market?

The market study bifurcates the worldwide CRISPR Technology market on the basis of product type, regions, application, and end-user industry. The insights are backed with the aid of accurate and easy to understand graphs, tables, and figures.

Role of CRISPR Technology Market Report:

Save and decrease time sporting out entry-level analysis by evaluatng the growth, size, key players and segments in the global CRISPR Technology Market.

Highlights vital business priorities in order to help companies to realign their business strategies.

The crucial findings and recommendations focuses key progressive industry trends in the CRISPR Technology Market, thereby allowing players to build effective long term strategies.

Develop/modify business growth plans by using substantial expansion offering developed and emerging markets.

Scrutinize detailed worldwide market trends andoverview coupled with the factors driving the market, as well as those inhibit it.

Intensify the decision-making process by understanding the strategies that support commercial interest with admire to merchandise, segmentation and industry verticals.

Any Query? Feel Free To Inquiry Here:https://marketresearch.biz/report/crispr-technology-market/#inquiry

Table of Contents

Outlook of the CRISPR Technology Market: This section covers the key manufacturers, market segments, study aim and analysis of market size for the 2020-2029 forecast period.

Presumption and Growth Trends Highlighted until 2029: This prospects based on 3 section such as growth rate of key producers, industry trends, and manufacturing estimation.

CRISPR Technology Player Market Share: This consist player production, revenue, and price calculation at the side of other chapters, such as growth plans and mergers and acquisitions, products include with the aid of top players and served areas and headquarters distribution.

Market size: Size of the market includes analysis of price, market share of the production value and market share of production.

Company profiles: Here, new entrants and leading players in the CRISPR Technology market are analysed based on gross margin, revenue, sales area, vital products, price and production.

CRISPR Technology Analysis of the market value chain and sales channel: Covering analysis of distributor, value chain, customer and sales channel.

Market forecast: In this part of the report, the analyst have targeted on the forecast of the value of production, the forecast of consumption by region, the forecast of production by region, the forecast of manufacturing and earnings and the regional forecast.

Request The Complete TOC Of This Report:https://marketresearch.biz/report/crispr-technology-market/#toc

Contact:

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

Email:inquiry@marketresearch.biz

Address: 420 Lexington Avenue, Suite 300, New York City, NY 10170, United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz/

Read more:
CRISPR Technology Market Segmentation, Industry Growth and Competitive Landscape Trends Forecast 2020-2029 | By MarketResearch.Biz - NJ MMA News

The vaccine from Pfizer and BioNTech has shown potential in human trials. In a small trial, participants developed higher levels of COVID-19 antibodies than typically seen in infected people. (Reuters)

Sherlock Biosciences has partnered with Binx Health to scale its CRISPR-enabled COVID-19 test. The company plans to make the test available at the point-of-care and in other places like grocery stores, making it the first CRISPR product to come to market. (Forbes)

Submit a cover design for MM&Ms Hall of Femme issue. Design a cover that celebrates the inspirational women who are leading the industry, raising their voices and exerting their influence to make real change happen to enter the contest. The deadline is July 31. (MM&M)

Some government COVID-19 research contracts do not require the drug to be affordable. A report found some contracts allowed companies to bypass laws that ensure taxpayer-funded treatments or vaccines are affordable. (STAT)

Drug companies are suing to block a Minnesota insulin law. The law, which was to go into effect Wednesday, would allow patients to get insulin for $35 and was intended to stop people from rationing the drug because they couldnt afford it. (STAT)

View post:
Five things for pharma marketers to know: Thursday, July 2, 2020 - Roundup - MM&M - Medical Marketing and Media

Base editing, a new player in the gene editing arena, could have an important role in the development of immune-based cell therapies to treat solid tumors. Using cell therapies, such as CAR-T cells, in solid tumors remains challenging: the current word on the street is that such chimeric antigen receptors (CARs) will need multiple gene modifications to make them efficient and it is in this space that base editing could have a substantial advantage.Immune-cell-based therapy is an exciting cell therapy approach to treat cancer where the natural defenses of a patients immune system are used to target and kill cancer cells. Hopes were high following the initial FDA approvals of the first autologous CAR-T therapies for Novartis KYMRIAH (Aug 2017) and Gilead/Kite Pharmas YESCARTA (Oct 2017), both for blood-based cancers, but translating these successes into solid tumors remains a challenge. This is a consequence of the complexity and heterogeneity of solid tumors together with the immune inhibitory nature of the tumor microenvironment.For T cell-based therapies to work, the patient is treated with modified T cells that are rendered capable of identifying and killing tumor cells and, through this, generating a wider immune response against the tumor. Two key approaches used to modify T cells are through expressing a T cell receptor (TCR) known to target the tumor cell or a CAR. Other approaches include using and/or modifying natural killer cells, gamma delta cells or tumor infiltrating lymphocytes. It is not clear which approach will provide the most effective treatment option and in fact it might be that each tumor type responds better to one approach or to a combination of approaches. Irrespective of the approach, it is clear that the current therapies all face similar challenges; the risk of graft vs host disease (GvHD), a lack of durable remissions, on-target or off-target toxicity and cytokine release syndrome.Another layer of complexity for T cell-based therapies lies with the source of T cellsusing the patients own (autologous T cells), or a donor or iPSC-derived T cells (allogeneic). Each approach has advantages and challenges. Briefly, autologous treatments are attractive because they mitigate the risk of immune rejection and GvHD when infused back into the patient. However, they require a complex manufacturing process that necessitates specialist equipment local to the patient to enable the isolation of their T cells followed by rapid manufacture to transform them into engineered T cells ready to infuse back into the patient. At all points during this manufacturing pipeline, the product must be kept sterile and tracible to ensure the correct cells are transfused back into the correct patient. The allogeneic T cells approach is appealing because of the possibility that these could be engineered to be universal donor cells (suitable for all or most patients). Such cells can be manufactured in bulk and administered to multiple patients all over the world. This bulk manufacturing would attract cost-savings once a critical mass of therapy is reached. It could also allow for engineered T cells to be available on-tap to any patient, a game-changer for particular patients whose own T cell count is either too low for engineering, or that transduce poorly with the engineered construct during manufacture. The challenge for allogeneic T cell therapies is the ability to generate cloaked T cells that do not provoke an immune-response in the patient, as this could kill the engineered T cells after transplantation such that they have no efficacy or potentially lead to the death of the patient as a result of a disseminated cytokine storm. Despite these challenges, in April 2019 the US Food and Drug Administration (FDA) approved the first allogeneic CAR-T for investigational use in patients with multiple myeloma and more are expected to follow.To try and achieve a stealth allogeneic T cell that flies under the radar of the patients immune system, genetic engineering is key. Although T cells can be engineered to express a specific TCR or CAR, additional genetic changes are required to provide a cloak of invisibility, prolong the survival of the cells in the patient and enable them to function in an immune suppressive tumor microenvironment. From a simplistic point of view, one could view the modified CAR or TCR as a sat nav, with the T cell being the engine. You need both to get to your destination and, if youre able to improve your engine, its possible the outcome could be achieved faster and in a more reliable fashion. There are several gene knockouts or gene knockdowns that are seen as a natural first step to improving the properties of engineered allogeneic T cells and these are summarized in the table below:As there are multiple gene knockout options, a gene engineering technology capable of making multiple gene edits with as few off-target effects as possible is needed. Indeed, it is conceivable that an effective allogeneic T cell-based therapy might require ten or more gene edits.This prompts the question What is the best gene editing platform or technology to support multiple gene edits? On the surface of it, and owing to its phenomenal adoption in research labs worldwide over the past decade, most currently use the gene editing approach provided by CRISPR-Cas9. CRISPR was first commercialized in 2012 and quite staggeringly made its debut in a clinical trial for cell therapy in June 2016. Although CRISPR is an efficient gene editing tool, its mode of action of generating double-strand breaks in the DNA could be a source of concern. DNA double-strand breaks, which tend to be repaired by the cells repair machinery in an error prone fashion, can cause unintended changes in the genome of engineered cells. Although there are methods for minimizing these off-target effects when single genes are targeted, targeting multiple genes in one cell all at the same time could lead to genome-altering insertions, deletions and/or chromosomal translocations. The impact of this on a patient could be that the cell therapy is effective but the off-target genetic changes lead to deleterious side-effects, impacting patient recovery and potentially survival. Well-known alternatives to CRISPR include transcription activator-like effector nucleases (TALENS) and zinc finger nucleases (ZFN). These approaches have slightly different safety profiles to CRISPR and while optimized for single gene edits or knockouts, multiple gene knockouts still present a challenge for these technologies. Freedom to operate using these technologies in the therapeutics space can also be challenging, particularly for start-up and biotech companies.The potential deleterious impact of off-target effects, particularly for multiple gene edits has opened the door to a newcomer on the gene engineering scene: base editing. This technology first gained prominence from peer-reviewed papers published by researchers from Harvard University.1 Others, such as Rutgers University, have also developed base editing platforms.2 In brief, base editing uses a deaminase enzyme to make a specific base pair change in the DNA. The base pair alteration can either be an A to G or a C to T depending on which deaminase is used. Importantly, the CRISPR-Cas system is used to guide the deaminase to the base pair that is going to be altered, but in this version of CRISPR-Cas, a DNA double-strand break is not made, meaning that the off-target effects with base editing in terms of insertions, deletions or translocations should be substantially reduced.On the surface, this crucial characteristic makes base editing an excellent choice of gene editor for cell therapyit can be used to specifically knock-out multiple genes through the introduction of stop codons or splice site disruptions with limited capacity to introduce substantial, large-scale chromosomal abnormalities. However, as base editing was first published in May 2016,1 substantial research is required to understand fully the utility of base editing in the therapeutic space and to appreciate its advantages and challenges compared with standard gene editing approaches, such as CRISPR-Cas, TALENs and ZFNs.As is somewhat expected of a fashionable area for scientific research, the gene editing space does not stand-still for very long: Prime editing has followed hot on the heels of base editing. Unlike base editing, which makes changes to specific base pairs in the DNA, prime editing allows changes to be made to a run of base pairs by forcing the cell to use a DNA copying system that exists naturally in cells as part of the DNA repair mechanism. Initial data suggest3 that prime editing has higher off-target effects compared with base editing, in terms of introducing insertions and deletions, and more work is needed to understand the comparison and utility of base editing vs. prime editing. It will be interesting to see how prime editing evolves over the months and years within the cell and gene therapy space.Although cell therapy has demonstrated its potential for driving complete remissions in some patients with hematological cancers, the next big step is to translate these early successes into patients with solid tumors. However, due to the complexity of solid tumors, this is not a simple or straight-forward process and multiple factors need to be considered. While the sat nav in the form of an engineered TCR or CAR is crucial, the T cell engine could be the natural starting point for improving efficacy in patients with solid tumors, as could the use of allogeneic rather than autologous approaches. The multiple edits that will be needed to deliver a stealth, engineered, allogeneic off-the-shelf T cell are only now being investigated in earnest and it could be that the new kid on the block, base editing, provides a compelling route forward.References1. Komor, A.C., Kim, Y.B., Packer, M.S., Zuris, J.A. and Liu, D.R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 533(7603), 420424. Doi:10.1038/nature179462. Horizon Discovery to provide access to novel base editing technology, January 2020;https://horizondiscovery.com/en/news/2020/Horizon-Discovery-to-provide-access-to-novel-base-editing-technology (accessed May 2020)3. Anzalone, A.V., Randolph, P.B., Davis, J.R., et al. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 576(7785), 149157. doi:10.1038/s41586-019-1711-4Dr. Jonathan Frampton is a business development professional who has been working for Horizon Discovery for the past 9 years and currently as their Corporate Development Partner. He is always scouting for exciting novel technology that could complement Horizons already extensive gene engineering toolkit. In addition to this he works closely with Horizons partners to manage out-licensing opportunities.

More:
Cell Therapy For Solid Tumors - Contract Pharma

Wall Street brokerage firm analysts have placed aBuy rating on shares of CRISPR Therapeutics AG (:CRSP). Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 2.30 on the shares. Based on a recent trade, the shares are hovering around $72.50 which, according to analysts, yield significant upside potential to the $75.88 consensus target price.

When it comes to investing in the equity market, discipline can play a major role in achieving ones goals. A few bad moves can send the investors confidence spiraling. Acting purely on emotion can lead to impulsive decisions that may cause the losses to pile up. Creating a solid plan and following through with the plan can help investors stay on track and focus on the proper details. Markets are constantly going up and down and the investing ride can sometimes be a bumpy one. Being able to see the big picture and focus on the important data can help keep the investor tuned in to the right channel. Investors who expect to jump into the market and immediately start raking in the profits may find out fairly quickly that trading without a plan can be a recipe for defeat.

Although the investing process is fairly straightforward, securing consistent returns in the stock market is not easy. Throwing hard earned money at un-researched investments can eventually lead the investor down the road to ruin. Every individual investor may have different goals when starting out. Aligning these goals with a specific plan can create a solid foundation for the future. Nobody can predict what the future will hold, but being aware of market conditions can be a great asset when attempting to navigate the terrain while mitigating risk. Once the vision of the individual investor is clear, the road to sustaining profits may be much easier to travel.

As company earnings reports continue to roll in, investors will be watching to see which companies hit their numbers for the last reporting period. Investors will also be watching which sectors are reporting the best earnings numbers. A positive overall earnings season could mean that the stock market could keep climbing. Many investors may be cautious with the market trading at current levels. Even though the gloom and doom prognosticators are out in full force, investors have to do the research and decide for themselves which way they believe the market will move in the next couple of months.

One of the most important factors that investors look at when examining stocks is the consistency of earnings results. When the quarterly earnings report is released, investors watch closely to see if the company is performing up to expectations. A company that fails to meet projections may see large price swings following the report. Of course one bad quarter may not signal trouble, but a company that continually disappoints during earnings season may need to be further examined to help figure out what is going on. Experienced investors will closely watch stock price movements before and after earnings events in order to gain a truer understanding of how the market is reacting to the reports.

Earnings estimates can also be manipulated, as the analysts are inclined to minimize them so that it increases the chances that a stock will beat the artificially lowered estimate in order to get inexperienced investors to buy.

RSI

CRISPR Therapeutics AG (:CRSP)s shares may have a significant upside to the consensus target of75.88, but how has it been performing relative to the market? The stocks price is 72.50 and their relative strength index (RSI) stands at 60.88. RSI is a technical oscillator that shows price strength by comparing upward and downward movements. It indicates oversold and overbought price levels for a stock.

Individual investors often strive to create a solid strategy before trying to take on the market. Setting up realistic, attainable goals, may be a good place for the amateur to start. There are many different approaches that the investor can take when getting into the stock market. Some investors will try to follow strategies that have worked for others in the past. Sometimes this will work, and sometimes it will not. Markets and economic landscapes are constantly changing. A strategy that worked yesterday may not work again tomorrow. Investors who put in the time to do the necessary homework may find themselves much better off when the market decides to rear its ugly head at some point down the road.

CRISPR Therapeutics AG (:CRSP) shares are moving-1.35% trading at $72.50 today.

See the original post here:
Analyst Activity Update on CRISPR Therapeutics AG (:CRSP) - Pineville

ZUG, Switzerland and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 6,428,572 common shares at a public offering price of $70.00 per share. In addition, the underwriters have a 30-day option to purchase up to an additional 964,285 common shares at the public offering price less the underwriting discount. CRISPR Therapeutics anticipates its gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $450.0 million, excluding any exercise of the underwriters option to purchase additional shares. The offering is expected to close on or about July 6, 2020, subject to customary closing conditions.

Goldman Sachs & Co. LLC, BofA Securities and Jefferies are acting as joint book-running managers for the offering. Canaccord Genuity, William Blair, SunTrust Robinson Humphrey and Roth Capital Partners are acting as co-managers for the offering.

The common shares will be offered and sold pursuant to the Companys previously filed automatically effective shelf registration statement on Form S-3 (File No. 333-227427) filed with the U.S. Securities and Exchange Commission (the SEC) on September 19, 2018. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on June 29, 2020. The final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SECs website at http://www.sec.gov. A copy of the final prospectus supplement may be obtained, when available, from Goldman Sachs & Co. LLC by mail at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; from BofA Securities by mail at NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; or from Jefferies, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340, or by email at prospectus_department@jefferies.com.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding CRISPR Therapeutics anticipated public offering. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, such as the expected closing date, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and the satisfaction of customary closing conditions related to the offering. These and other risks and uncertainties are described in greater detail in the section entitled Risk Factors in CRISPR Therapeutics Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on February 12, 2020, the prospectus supplement related to the public offering and other filings that CRISPR Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent CRISPR Therapeutics views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. CRISPR Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel EidesWCG on behalf of CRISPR+1 617-337-4167reides@wcgworld.com

Follow this link:
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares - July 01, 2020 - BioSpace

Transparency Market Research (TMR) has published a new report titled, CRISPR and Cas GenesMarket Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026. According to the report, the globalCRISPR and Cas genes marketwas valued at US$ 7,234.5 Mn by 2026, expanding at a CAGR of around 20.1% from 2018 to 2026. Increase in applications of CRISPR and Cas gene editing technology in bacteria and usage of gene editing technology for prevention of various diseases are the major factors anticipated to drive the market from 2018 to 2026. Rise in need of alternative medicine for chronic diseases and increase in investments by key players in Asia Pacific are projected to propel the market during the forecast period.

Planning To Lay Down Future Strategy? Request Brochure Of CRISPR and Cas Genes Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26417

Increase in Usage of DNA-free Cas

DNA-free Cas9 is most commonly used with synthetic crRNA tracrRNA and chosen by researchers who strive to avoid unwanted vector DNA integration into their genomic DNA. CRISPR-Cas9 utilizing mRNA or protein is ideal for applications such as knocking of a fluorescent reporter using HDR or knockout cell line generation. Advantages such as gene editing with DNA-free CRISPR-Cas9 components to reduce potential off-targets and potential usage of CRISPR-Cas9 gene editing to find correlations with human diseases in model systems drive the segment.

Rise in Incidence of Genetic Disorders and Increase in Applications of CRISPR and Cas Genesto Propel Market

Genetic diseases are generally termed as rare diseases. According to NCBI, prevalence of these rare diseases is approximately 5 in 10,000. There are 6,000 to 8,000 rare diseases, with 250 to 280 new diseases diagnosed every year. Hence, 6% to 8% of the global population is projected to be affected by rare diseases i.e., genetic diseases in the near future. Researchers are developing treatments for these diseases with applications of new technologies such as CRISPR. The applications of CRISPR technology are expanding in other industrial sectors. This is expected to drive the market during the forecast period. Usage of CRISPR/Cas9 technology in plant research has enabled the investigation of plant biology in detail which has helped to create innovative applications in crop breeding. Site-directed mutagenesis and site-specific integration of a gene, which is also called knock-in, are important in precision crop breeding. Cas9/gRNA-mediated site-directed mutagenesis and knock-in is widely used in rice and Arabidopsis protoplasts. CRISPR/Cas9 provides a simple method to generate a DSB at a target site to trigger HDR repair.

To Obtain All-Inclusive Information On Forecast Analysis Of CRISPR and Cas Genes Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=26417

Ethical Issues Concerning Gene Editing Technology to Restrain Market

Any changes in the human genome are made in the germline, and hence are expected to be passed on to the future generations. The safety and efficacy concerns with genome editing have gained momentum with the discovery of CRISPR, as it has the potential to make accurate use of genome editing technologies. Major ethical issues concerning the human genome editing technology are disturbance of the ecological equilibrium, patent regulations concerning CRISPR/Cas9 gene technology, non-therapeutic interventions using human genome, and formation of chimera which has the risk of violation of the order of nature and giving rise to moral confusion for treating organisms.

Asia Pacific Market to Witness Exponential Growth

In terms of revenue, the CRISPR and Cas genes market in Asia Pacific is expected to expand at a CAGR of 22.0% during the forecast period. Growth of the market in the region can be attributed to increase in incidence of chronic diseases such as cancer and the need of development of genetic engineered treatment options. According to the report, Call for Action: Expanding Cancer Care for Women in India, 2017, an estimated 0.7 million women in India are suffering from cancer. China dominated the CRISPR and Cas genes market in Asia Pacific. In 2016, scientists based in China launched the first known human trials of CRISPR, the genomic tech that involves slicing and dicing the bodys very source code to fight cancer. Japan was the second largest market for CRISPR and Cas genes in Asia Pacific.

Request For Covid19 Impact Analysis

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=26417

Addgene, Thermo Fisher Scientific, Inc., and Integrated DNA Technologies, Inc. to Lead Market

The report also provides profiles of leading players operating in the global CRISPR and Cas market such as Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

More:
CRISPR and Cas Genes Market Trends, Business Strategies and Opportunities With Key Players Analysis 2026 - 3rd Watch News

With genetic engineering, we will be able to increase the complexity of our DNA, and improve the human race. But it will be a slow process, because one will have to wait about 18 years to see the effect of changes to the genetic code. - Stephen Hawking

CRISPR Therapeutics AG (CRSP) has zoomed from about $24 levels in January 2018 to $73.09 as of June 25, 2020, and thats a massive appreciation of about 300% in a space of 30 months. It is an efficiently managed and profitable gene-editing company that looks all set to go places once the COVID-19 disruption is contained.

Im bullish on biotech and innovative technologies within the healthcare sector and have been tweeting and reporting about relevant stocks and ETFs in The Lead-Lag Report from as early as February 2020.

Image Source: Twitter

Though I am bullish on CRSP as a long-term pick, now is not the right time or price to invest in it. COVID-19 cases have started spinning out of control, and while we may not experience another lockdown, the surge in cases can disrupt the companys operations. Before spelling out the strategy to be followed, here are a few facts:

In its Q1 2020 filing with the SEC, the company has listed the following COVID-19-specific risks to its operations:

1. The companys clinical trials for products developed for the treatment of hemoglobinopathies and immuno-oncology-based treatment have been impacted. According to the company, COVID-19 disruption will continue to impact these trials adversely in future too, due to a variety of reasons, including: (A) ICU beds that are required for trials have been diverted for treating the virus-infected; (B) Investigators did/may not want to expose candidates to COVID-19, and (C) Shortage of staff at the trial location.

2. Some of the suppliers of the company (e.g., materials, drugs, quality testing, and samples) have paused their operations.

3. Most of the companys staff was in WFH mode as of late April 2020.

These factors have impacted the companys operations as of late April 2020, and even though many facilities had reopened in May 2020, some or many may now again be impacted by the virus resurgence. The point is that as long as the COVID-19 disruption continues, CRSPs trials and operations will continue to be impacted, upsetting its pipeline. No medical research organization is sure how and by when the virus will be contained.

The global gene therapy market is estimated to grow at an annualized rate of 40% in the next 10 years. In money terms, it is expected to be worth $10 billion by 2030.

Image Source: Roots Analysis

As per Roots Analysis, a research firm, the gene-editing market is likely to witness a small decline during the COVID-19 disruption. Once the virus is contained, or when there is clarity on virus containment, the gene-editing market will get back on its growth path.

As of Q1 2020, CRSP has $889.7 million cash and equivalents in its books. This accumulated cash is not because of past operational profits, but because the company has issued stock in the last 3 years.

Image Source: Seeking Alpha

Between 2018 and 2020, the company has issued $1.15 billion worth of stock and now looks very richly valued. Here are a few numbers:

1. CRSPs TTM P/E (GAAP) is a whopping 95.41 as compared to the sector median of 33.93.

2. Its TTM EV/EBITDA is a massive 131.30 as compared to the sector median of 17.70.

3. The Forward Price/Sales is way too high at 247.50 versus the sector median of 7.71.

Slice or dice it any which way, CRSP is a very expensive stock.

CRSP is an exciting stock with a bright future. Analysts such as Oppenheimer, Jefferies, Chardan Capital, and Canaccord Genuity have assigned it a buy rating, and many independent analysts are bullish on the stock.

I too am bullish about its growth prospects but am not putting out a buy call at this price because the stock is extremely expensive.

Q2 2020, as discussed above, is likely to be adversely impacted, and there is no clarity on when the COVID-19 disruption will end. The companys product pipeline is likely to slow down as well.

Considering all positives and negatives, I would rely more on price action than news. The stock hit a low of about $33 in March 2020 and is priced at $73.09 as of June 25, 2020. I would start accumulating the stock in small quantities after it retraces 50% of its rise from its March lows, or approximately $53. I would buy small parcels at this price and keep adding on dips.

If suddenly there is clarity on when the virus disruption is going to end, or if its severity (in terms of morbidity) has greatly reduced, I would buy this stock at whatever rate it is available on that day.

*Like this article? Don't forget to hit the "Follow" button above!

Subscribers told of melt-up March 31. Now what?

Sometimes, you might not realize your biggest portfolio risks until its too late.

Thats why its important to pay attention to the right market data, analysis, and insights on a daily basis. Being a passive investor puts you at unnecessary risk. When you stay informed on key signals and indicators, you'll take control of your financial future.

My award-winning market research gives you everything you need to know each day, so you can be ready to act when it matters most.

Click here to gain access and try the Lead-Lag Report FREE for 14 days.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This writing is for informational purposes only and Lead-Lag Publishing, LLC undertakes no obligation to update this article even if the opinions expressed change. It does not constitute an offer to sell, a solicitation to buy, or a recommendation regarding any securities transaction. It also does not offer to provide advisory or other services in any jurisdiction. The information contained in this writing should not be construed as financial or investment advice on any subject matter. Lead-Lag Publishing, LLC expressly disclaims all liability in respect to actions taken based on any or all of the information on this writing.

Read more:
Crispr Therapeutics AG: Risks, Rewards, And Valuation - Seeking Alpha